TRANSFER OF LYMPHOCYTIC CHORIOMENINGITIS DISEASE IN BETA(2)-MICROGLOBULIN-DEFICIENT MICE BY CD4+ T-CELLS

Daniel Quinn, AJ ZAJAC, JA FRELINGER, D MULLER

    Research output: Contribution to journalArticle

    33 Citations (Scopus)

    Abstract

    In this study we have investigated the role of CD4+, MHC class II-restricted cytotoxic T lymphocytes (CTLs) in the disease caused by lymphocytic choriomeningitis virus (LCMV) in beta2-Microglobulin deficient (beta2M-) mice. Intracranial (i.c.) infection with LCMV resulted in death of six out Of 11 beta2M- mice. Mice that survived showed a marked loss in body weight. Death and loss of body weight could be prevented by immunosuppressing the mice with irradiation or cyclosporine prior to i.c. injection of LCMV. This treatment also prevented induction of virus-specific, MHC class II-restricted CTL following peripheral inoculation with LCMV. In vivo depletion of CD4+ cells with antibody also prevented death following i.c. injection whereas in vivo depletion of CD8+ cells had no effect. Disease could be transferred to recipient beta2M- mice by adoptive transfer of beta2M- derived immune spleen cells. Transfer of non-immune spleen cells did not result in illness. In vitro treatment of immune spleen cells with anti-CD4 antibody and complement eliminated class 11-restricted CTL activity and also prevented mortality of recipients after adoptive transfer. Treatment with anti-CD8 antibody had no effect. We were unable to transfer LCM disease to beta2M- recipients by adoptive transfer of immune spleen cells from C57BL/6 mice. These results suggest that, unlike normal mice, the pathology of LCM disease in beta2M- mice is dependent upon virus-specific, CD4+CD8-, MHC class II-restricted T cells.
    LanguageEnglish
    Pages1193-1198
    JournalInternational Immunology
    Volume5
    Issue number10
    DOIs
    Publication statusPublished - Oct 1993

    Fingerprint

    Lymphocytic Choriomeningitis
    beta 2-Microglobulin
    Lymphocytic choriomeningitis virus
    T-Lymphocytes
    Adoptive Transfer
    Cytotoxic T-Lymphocytes
    Spleen
    Anti-Idiotypic Antibodies
    Body Weight
    Virus Activation
    Injections
    Inbred C57BL Mouse
    Cyclosporine
    Therapeutics
    Pathology
    Viruses
    Mortality
    Antibodies

    Cite this

    Quinn, Daniel ; ZAJAC, AJ ; FRELINGER, JA ; MULLER, D. / TRANSFER OF LYMPHOCYTIC CHORIOMENINGITIS DISEASE IN BETA(2)-MICROGLOBULIN-DEFICIENT MICE BY CD4+ T-CELLS. In: International Immunology. 1993 ; Vol. 5, No. 10. pp. 1193-1198.
    @article{94740bdbf9fe467ebeef2a55798c615e,
    title = "TRANSFER OF LYMPHOCYTIC CHORIOMENINGITIS DISEASE IN BETA(2)-MICROGLOBULIN-DEFICIENT MICE BY CD4+ T-CELLS",
    abstract = "In this study we have investigated the role of CD4+, MHC class II-restricted cytotoxic T lymphocytes (CTLs) in the disease caused by lymphocytic choriomeningitis virus (LCMV) in beta2-Microglobulin deficient (beta2M-) mice. Intracranial (i.c.) infection with LCMV resulted in death of six out Of 11 beta2M- mice. Mice that survived showed a marked loss in body weight. Death and loss of body weight could be prevented by immunosuppressing the mice with irradiation or cyclosporine prior to i.c. injection of LCMV. This treatment also prevented induction of virus-specific, MHC class II-restricted CTL following peripheral inoculation with LCMV. In vivo depletion of CD4+ cells with antibody also prevented death following i.c. injection whereas in vivo depletion of CD8+ cells had no effect. Disease could be transferred to recipient beta2M- mice by adoptive transfer of beta2M- derived immune spleen cells. Transfer of non-immune spleen cells did not result in illness. In vitro treatment of immune spleen cells with anti-CD4 antibody and complement eliminated class 11-restricted CTL activity and also prevented mortality of recipients after adoptive transfer. Treatment with anti-CD8 antibody had no effect. We were unable to transfer LCM disease to beta2M- recipients by adoptive transfer of immune spleen cells from C57BL/6 mice. These results suggest that, unlike normal mice, the pathology of LCM disease in beta2M- mice is dependent upon virus-specific, CD4+CD8-, MHC class II-restricted T cells.",
    author = "Daniel Quinn and AJ ZAJAC and JA FRELINGER and D MULLER",
    year = "1993",
    month = "10",
    doi = "10.1093/intimm/5.10.1193",
    language = "English",
    volume = "5",
    pages = "1193--1198",
    journal = "International Immunology",
    issn = "0953-8178",
    number = "10",

    }

    TRANSFER OF LYMPHOCYTIC CHORIOMENINGITIS DISEASE IN BETA(2)-MICROGLOBULIN-DEFICIENT MICE BY CD4+ T-CELLS. / Quinn, Daniel; ZAJAC, AJ; FRELINGER, JA; MULLER, D.

    In: International Immunology, Vol. 5, No. 10, 10.1993, p. 1193-1198.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - TRANSFER OF LYMPHOCYTIC CHORIOMENINGITIS DISEASE IN BETA(2)-MICROGLOBULIN-DEFICIENT MICE BY CD4+ T-CELLS

    AU - Quinn, Daniel

    AU - ZAJAC, AJ

    AU - FRELINGER, JA

    AU - MULLER, D

    PY - 1993/10

    Y1 - 1993/10

    N2 - In this study we have investigated the role of CD4+, MHC class II-restricted cytotoxic T lymphocytes (CTLs) in the disease caused by lymphocytic choriomeningitis virus (LCMV) in beta2-Microglobulin deficient (beta2M-) mice. Intracranial (i.c.) infection with LCMV resulted in death of six out Of 11 beta2M- mice. Mice that survived showed a marked loss in body weight. Death and loss of body weight could be prevented by immunosuppressing the mice with irradiation or cyclosporine prior to i.c. injection of LCMV. This treatment also prevented induction of virus-specific, MHC class II-restricted CTL following peripheral inoculation with LCMV. In vivo depletion of CD4+ cells with antibody also prevented death following i.c. injection whereas in vivo depletion of CD8+ cells had no effect. Disease could be transferred to recipient beta2M- mice by adoptive transfer of beta2M- derived immune spleen cells. Transfer of non-immune spleen cells did not result in illness. In vitro treatment of immune spleen cells with anti-CD4 antibody and complement eliminated class 11-restricted CTL activity and also prevented mortality of recipients after adoptive transfer. Treatment with anti-CD8 antibody had no effect. We were unable to transfer LCM disease to beta2M- recipients by adoptive transfer of immune spleen cells from C57BL/6 mice. These results suggest that, unlike normal mice, the pathology of LCM disease in beta2M- mice is dependent upon virus-specific, CD4+CD8-, MHC class II-restricted T cells.

    AB - In this study we have investigated the role of CD4+, MHC class II-restricted cytotoxic T lymphocytes (CTLs) in the disease caused by lymphocytic choriomeningitis virus (LCMV) in beta2-Microglobulin deficient (beta2M-) mice. Intracranial (i.c.) infection with LCMV resulted in death of six out Of 11 beta2M- mice. Mice that survived showed a marked loss in body weight. Death and loss of body weight could be prevented by immunosuppressing the mice with irradiation or cyclosporine prior to i.c. injection of LCMV. This treatment also prevented induction of virus-specific, MHC class II-restricted CTL following peripheral inoculation with LCMV. In vivo depletion of CD4+ cells with antibody also prevented death following i.c. injection whereas in vivo depletion of CD8+ cells had no effect. Disease could be transferred to recipient beta2M- mice by adoptive transfer of beta2M- derived immune spleen cells. Transfer of non-immune spleen cells did not result in illness. In vitro treatment of immune spleen cells with anti-CD4 antibody and complement eliminated class 11-restricted CTL activity and also prevented mortality of recipients after adoptive transfer. Treatment with anti-CD8 antibody had no effect. We were unable to transfer LCM disease to beta2M- recipients by adoptive transfer of immune spleen cells from C57BL/6 mice. These results suggest that, unlike normal mice, the pathology of LCM disease in beta2M- mice is dependent upon virus-specific, CD4+CD8-, MHC class II-restricted T cells.

    U2 - 10.1093/intimm/5.10.1193

    DO - 10.1093/intimm/5.10.1193

    M3 - Article

    VL - 5

    SP - 1193

    EP - 1198

    JO - International Immunology

    T2 - International Immunology

    JF - International Immunology

    SN - 0953-8178

    IS - 10

    ER -